

1. Record Nr.	UNISALENTO991003699999707536
Autore	Savatier, René
Titolo	Les métamorphoses économiques et sociales du droit privé d'aujourd'hui. 3. serie, Approfondissement d'un droit renouvelé / René Savatier
Pubbl/distr/stampa	Paris : Dalloz, 1959
Descrizione fisica	268 p. ; 22 cm.
Disciplina	347.44
Soggetti	Diritto privato - Francia
Lingua di pubblicazione	Francese
Formato	Materiale a stampa
Livello bibliografico	Monografia
2. Record Nr.	UNINA9910782307603321
Autore	Shorter Edward
Titolo	Before Prozac [[electronic resource]] : the troubled history of mood disorders in psychiatry // Edward Shorter
Pubbl/distr/stampa	Oxford ; ; New York, : Oxford University Press, 2009
ISBN	0-19-770572-3 0-19-045136-X 1-281-82598-0 9786611825980 0-19-970933-5
Descrizione fisica	1 online resource (321 p.)
Disciplina	616.85/27061
Soggetti	Affective disorders - Chemotherapy - United States - History Psychotropic drugs - United States - History Psychopharmacology - United States - History Serotonin uptake inhibitors - Therapeutic use - History Psychotropic drugs industry - United States - History Pharmaceutical policy - United States - History
Lingua di pubblicazione	Inglese

Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Before psychopharmacology -- The first drug set -- Power play -- Killer drugs! -- Death sentences -- "The plague of affective disorders" -- Losing ground -- What now?
Sommario/riassunto	Psychiatry today is a barren tundra, writes medical historian Edward Shorter, where drugs that don't work are used to treat diseases that don't exist. In this provocative volume, Shorter illuminates this dismal landscape, in a revealing account of why psychiatry is "losing ground" in the struggle to treat depression. Naturally, the book looks at such culprits as the pharmaceutical industry, which is not inclined to market drugs once the patent expires, leading to the endless introduction of new--but not necessarily better--drugs. But the heart of the book focuses on an unexpected villain: th